(-)deprenyl increases activities of Superoxide Dismutase (SOD) in striatum of dog brain
References (15)
- et al.
Life Sci.
(1990) - et al.
Life Sci.
(1991) - et al.
Exp. Neurol.
(1992) - et al.
Life Sci.
(1992) - et al.
Biochem. Pharmacol.
(1992) - et al.
Arch. Int. Pharmacodyn. Ther.
(1965) - et al.
J. Neur. Transm.
(1985)
Cited by (38)
Special Considerations for Diagnosing Behavior Problems in Older Pets
2018, Veterinary Clinics of North America - Small Animal PracticeCitation Excerpt :Selegiline (Anipryl; Pfizer Animal Health, New York, New York), which is only licensed for dogs, has shown improvement with CDS both clinically and in controlled laboratory experiments. It is suggested that selegiline may enhance dopamine and other catecholamines in the brain and may also act as a neuroprotective agent by acting on oxygen free radicals.45,47 Off-label use of selegiline in cats has also shown improvement in CDS-like signs.48
The effect of R-(-)-deprenyl administration on antioxidant enzymes in rat testis
2016, European Journal of PharmacologyCitation Excerpt :Indeed, deprenyl administration attenuated ROS production by 50% in diabetic rats (Sturza et al., 2015); significantly reduced the content of malondialdehyde (MDA), a marker of lipid peroxidation in cerebellum (Subramanian and James, 2010); and decreased the ischemia-induced elevation of MDA in brain (Seif-El-Nasr et al., 2008). Deprenyl not only decreases the ROS production, but also increases the activity of SODs in the brain of dogs (Carrillo et al., 1994a), rats (Carrillo et al., 1991), or mice (Carrillo et al., 1994b). To achieve an optimal increase, deprenyl needs to be administered for at least three weeks.
Cognitive Dysfunction Syndrome. A Disease of Canine and Feline Brain Aging
2012, Veterinary Clinics of North America - Small Animal PracticeCitation Excerpt :Selegiline (Anipryl; Pfizer Animal Health, New York, NY, USA) is a selective and irreversible inhibitor of monoamine oxidase B.59 It may enhance dopamine and other catecholamines in the cortex and hippocampus and has been shown both in the laboratory and clinic to improve signs consistent with CDS in dogs.59,61 Selegiline also may be neuroprotective possibly by reducing free radical production and/or increasing enzymes that scavenge free radicals such as superoxide dismutase and catalase.59,60 Selegiline is not licensed for use in cats but is used off label with anecdotal reports of improvement in CDS-like signs.62
Clinical signs and management of anxiety, sleeplessness, and cognitive dysfunction in the senior pet
2011, Veterinary Clinics of North America - Small Animal PracticeCitation Excerpt :It may act by enhancing dopamine and other catecholamines in the cortex and hippocampus and has been shown both in the laboratory and clinical setting to improve signs related to CDS. Selegiline is considered to be neuroprotective, potentially by increasing efficiency of superoxide dismutase and catalase for improved free radical scavenging, which may decrease nerve damage/degeneration.63 Selegiline is not licensed in cats; however, it has been used off label at the same dose with anecdotal reports of improvement in CDS-like signs.64
Behavior problems in geriatric pets
2005, Veterinary Clinics of North America - Small Animal PracticeCitation Excerpt :Selegiline increases brain 2-phenylethylamine (PEA), which is a neuromodulator that enhances dopamine and catecholamine function and may itself enhance cognitive function [45]. Selegiline may also contribute to a decrease in free radical load in the brain by inhibiting MAOB and increasing free radical clearance by enhancing the activity of enzymes like SOD [46]. Because alterations in neurotransmitter function can lead to behavior changes, such as increased irritability, decreased responsiveness to stimuli, fear, agitation, and altered sleep-wake cycles (as well as depression in human beings), antidepressants and anxiolytics might also be considered for some older pets.
Therapeutic agents for the treatment of cognitive dysfunction syndrome in senior dogs
2005, Progress in Neuro-Psychopharmacology and Biological Psychiatry